Abstract
The identification of the causes of cancer at the cellular level has led to the discovery of the Epidermal Growth Factor Receptor (EGFR)/Ras/Mitogen-Activated Protein Kinase (MAPK) signaling pathway as a target for the development of anti-cancer strategies. A variety of therapeutic approaches to inhibit the EGFR/Ras/MAP module are currently being tested in clinical trials or have even been approved for the treatment of some tumors. However, more efficient ways to block the EGFR/Ras/MAPK pathway in tumor cells still have to be developed. The subcellular localisation of each member of this module is of pertinent importance to ensure signaling. Accumulating evidence suggests that targeting/scaffold proteins regulate the assembly, localization and activity of EGFR/Ras/MAPK signal transduction components. In particular proteins that stimulate the lysosomal downregulation of the EGFR and the targeting of Ras regulators/effectors to Ras could contribute to improve strategies to inhibit EGFR/Ras signaling in cancer. These proteins include the Cbl/CIN85/endophilin pathway, caveolin, galectins, annexins, Impedes Mitogenic Signal Propagation (IMP), 14-3-3 and Kinase Suppressor of Ras (KSR). Here we will review the current literature regarding the potential of targeting/scaffold proteins to affect the lysosomal targeting of EGFR and the subcellular localization of the Ras/MAPK signaling cascade.
Keywords: EGF receptor, Ras/Raf/MAPK pathway, cancer, scaffolds, adaptors
Current Signal Transduction Therapy
Title: Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Volume: 1 Issue: 2
Author(s): Thomas Grewal, Francesc Tebar, Albert Pol and Carlos Enrich
Affiliation:
Keywords: EGF receptor, Ras/Raf/MAPK pathway, cancer, scaffolds, adaptors
Abstract: The identification of the causes of cancer at the cellular level has led to the discovery of the Epidermal Growth Factor Receptor (EGFR)/Ras/Mitogen-Activated Protein Kinase (MAPK) signaling pathway as a target for the development of anti-cancer strategies. A variety of therapeutic approaches to inhibit the EGFR/Ras/MAP module are currently being tested in clinical trials or have even been approved for the treatment of some tumors. However, more efficient ways to block the EGFR/Ras/MAPK pathway in tumor cells still have to be developed. The subcellular localisation of each member of this module is of pertinent importance to ensure signaling. Accumulating evidence suggests that targeting/scaffold proteins regulate the assembly, localization and activity of EGFR/Ras/MAPK signal transduction components. In particular proteins that stimulate the lysosomal downregulation of the EGFR and the targeting of Ras regulators/effectors to Ras could contribute to improve strategies to inhibit EGFR/Ras signaling in cancer. These proteins include the Cbl/CIN85/endophilin pathway, caveolin, galectins, annexins, Impedes Mitogenic Signal Propagation (IMP), 14-3-3 and Kinase Suppressor of Ras (KSR). Here we will review the current literature regarding the potential of targeting/scaffold proteins to affect the lysosomal targeting of EGFR and the subcellular localization of the Ras/MAPK signaling cascade.
Export Options
About this article
Cite this article as:
Grewal Thomas, Tebar Francesc, Pol Albert and Enrich Carlos, Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis, Current Signal Transduction Therapy 2006; 1 (2) . https://dx.doi.org/10.2174/157436206777012066
DOI https://dx.doi.org/10.2174/157436206777012066 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biologic Agents in the Treatment of Psoriasis
Recent Patents on Inflammation & Allergy Drug Discovery Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Shutting Down the Furnace: Preferential Killing of Cancer Cells with Mitochondrial-Targeting Molecules
Current Medicinal Chemistry Functional Multipotency of Stem Cells: A Conceptual Review of Neurotrophic Factor-Based Evidence and Its Role in Translational Research
Current Neuropharmacology Survivin Modulators: An Updated Patent Review (2011 - 2015)
Recent Patents on Anti-Cancer Drug Discovery Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science The Regulatory Role of Both MBNL1 and MBNL1-AS1 in Several Common Cancers
Current Pharmaceutical Design Regulatory T Cells and Cancer Therapy: An Old Story with a New Hope
Current Cancer Therapy Reviews Paris polyphylla: Chemical and Biological Prospectives
Anti-Cancer Agents in Medicinal Chemistry Insights into the Role of mTOR/AMPK as a Potential Target for Anticancer Therapy
Current Drug Therapy Roles of Tumor Microenvironment in Hepatocelluar Carcinoma
Current Cancer Therapy Reviews Piecing the Fragments Together: Dynamical Insights into the Enhancement of BRD4-BD1 (BET Protein) Druggability in Cancer Chemotherapy Using Novel 8-methyl-pyrrolo[1,2-a]pyrazin-1(2H)-one Derivatives
Current Pharmaceutical Biotechnology Curcumin Conjugates and Metallocomplexes as Lead Compounds for Development of Anticancer Agents - A Short Review
Current Bioactive Compounds A Novel Quinazoline-4-one Derivatives as a Promising Cytokine Inhibitors: Synthesis, Molecular Docking, and Structure-activity Relationship
Current Pharmaceutical Biotechnology Selective Inhibitors of Zinc-Dependent Histone Deacetylases. Therapeutic Targets Relevant to Cancer
Current Pharmaceutical Design Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy
Current Medicinal Chemistry L1 Retrotransposon and Retinoblastoma: Molecular Linkages Between Epigenetics and Cancer
Current Molecular Medicine Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Drug Metabolism and Individualized Medicine
Current Drug Metabolism